A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Phase
3Span
353 weeksSponsor
Seagen, a wholly owned subsidiary of PfizerPsychiko
Recruiting
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
Phase
2Span
176 weeksSponsor
PfizerKaisariani, Attikí
Recruiting
A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Phase
3Span
212 weeksSponsor
Seagen, a wholly owned subsidiary of PfizerCholargos
Recruiting
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Phase
3Span
293 weeksSponsor
Seagen, a wholly owned subsidiary of PfizerCholargos
Recruiting
Cholargos
Recruiting
1-5 of 5